These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 17684229

  • 1. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
    Aartsma-Rus A, van Ommen GJ.
    RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229
    [Abstract] [Full Text] [Related]

  • 2. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T, Maruyama R, Yokota T.
    Methods Mol Biol; 2018 Oct; 1687():143-155. PubMed ID: 29067661
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
    Aartsma-Rus A, Houlleberghs H, van Deutekom JC, van Ommen GJ, 't Hoen PA.
    Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
    [Abstract] [Full Text] [Related]

  • 5. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
    Maruyama R, Yokota T.
    Methods Mol Biol; 2018 Apr; 1828():79-90. PubMed ID: 30171536
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
    Touznik A, Lee JJ, Yokota T.
    Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
    [Abstract] [Full Text] [Related]

  • 9. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
    Niks EH, Aartsma-Rus A.
    Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
    [Abstract] [Full Text] [Related]

  • 10. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T.
    Mol Ther; 2017 Nov 01; 25(11):2561-2572. PubMed ID: 28865998
    [Abstract] [Full Text] [Related]

  • 11. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M, Takeshima Y, Nishio H.
    Brain Dev; 2016 Jan 01; 38(1):4-9. PubMed ID: 26094594
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC.
    BMC Med Genet; 2007 Jul 05; 8():43. PubMed ID: 17612397
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC.
    Gene Ther; 2004 Sep 05; 11(18):1391-8. PubMed ID: 15229633
    [Abstract] [Full Text] [Related]

  • 18. Exon-skipping events in candidates for clinical trials of morpholino.
    Nakano S, Ozasa S, Yoshioka K, Fujii I, Mitsui K, Nomura K, Kosuge H, Endo F, Matsukura M, Kimura S.
    Pediatr Int; 2011 Aug 05; 53(4):524-9. PubMed ID: 21342350
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.